

Chapter 4

Microbiome and Mental Health – Depression and Anxiety

Dr. Ashish Bansal

MBBS, MD Psychiatry (PGI Chandigarh) Fellowship in
Psychosexual Medicine

Rajlaxmi

Nursing Tutor, Rufaida College of Nursing Jamia Hamdard, New
Delhi

The link between gut health and mental well-being has attracted increasing attention, as growing research points to the gut microbiome's role in the onset and regulation of mood disorders, especially depression and anxiety. The idea that gut microbes can impact emotional and cognitive processes is rooted in the core concept of the microbiota-gut-brain axis (MGBA), where microbial byproducts, immune factors, and neural signaling influence brain activity.

The gut microbiome influences depression through several interconnected mechanisms, largely mediated by the microbiota-gut-brain axis (MGBA). One of the key pathways involves the production and regulation of neurotransmitters and neuromodulators by gut bacteria. For instance, certain microbes synthesize gamma-aminobutyric acid (GABA), serotonin precursors, dopamine, and other neuroactive compounds that can modulate mood and emotional regulation. Since approximately 90% of the body's serotonin is produced in the gut, disruptions in the microbiome can profoundly affect serotonin availability and signaling in the brain, potentially contributing to depressive symptoms.

Another important factor is the role of systemic inflammation driven by gut dysbiosis. An imbalance in the gut microbial community—known as dysbiosis—can compromise intestinal barrier integrity, leading to increased permeability or “leaky gut.” This allows bacterial components like lipopolysaccharides (LPS) to enter the bloodstream, triggering chronic low-grade

inflammation. Elevated inflammatory markers such as cytokines have been consistently observed in patients with depression and are thought to interfere with neurotransmitter metabolism and neuroplasticity, further exacerbating mood disorders.

Key Microbial Changes:

- Decreased levels of *Bifidobacterium* and *Lactobacillus*
- Increased *Clostridium* and *Oscillibacter* species
- Reduced microbial diversity[2]
- Preclinical studies using animal models have provided compelling evidence linking the gut microbiome to depressive behavior. Germ-free mice, which lack a microbiome, exhibit altered stress responses and anxiety-like behaviors. Introducing specific beneficial bacterial strains, such as *Lactobacillus* and *Bifidobacterium*, has been shown to alleviate these behaviors, suggesting a causal relationship. Similarly, fecal microbiota transplantation (FMT) experiments transferring microbiota from depressed individuals to rodents can induce depressive-like symptoms in the recipient animals, underscoring the microbiome's role in mood regulation.[3]
- Clinical research is increasingly investigating microbiome-targeted therapies for depression. Probiotics, sometimes called “psychobiotics” when used for mental health, have shown promise in reducing depressive symptoms in some studies, likely by restoring microbial balance, reducing inflammation, and modulating neurotransmitter pathways. Dietary interventions rich in fiber and fermented foods also support microbiome health and may indirectly benefit mood.

4.2 Anxiety and Gut Microbiota

Like depression, Anxiety disorders are among the most common mental health conditions globally, characterized by excessive fear, worry, and physiological symptoms such as restlessness, rapid heartbeat, and gastrointestinal discomfort. While traditionally understood through neurochemical and psychological frameworks, recent research has highlighted a strong connection between the gut microbiota and anxiety, mediated through the **microbiota-gut-brain axis (MGBA)**.

Common microbial alterations in anxiety include:

- Increased Firmicutes/Bacteroidetes ratio
- Elevated pro-inflammatory taxa like *Proteobacteria*
- Decreased SCFA-producing bacteria such as *Faecalibacterium prausnitzii*[4]

In humans, studies have shown associations between dysbiosis (an imbalance in gut microbiota) and increased levels of anxiety.

- **Probiotics (Psychobiotics):** Some clinical trials have found that specific probiotic strains can reduce anxiety symptoms in both healthy individuals and those with diagnosed anxiety disorders. For example, *Bifidobacterium longum* 1714 and *Lactobacillus helveticus* R0052 have shown promise in improving stress resilience and reducing anxiety scores.

- **Dietary Interventions:** Diets rich in fiber, polyphenols, and fermented foods can support microbial health and potentially reduce anxiety symptoms. Conversely, Western-style diets high in processed foods and sugars are associated with greater anxiety and lower microbial diversity.

Individuals with anxiety disorders often display reduced microbial diversity and lower levels of beneficial bacteria like *Bifidobacterium* and *Lactobacillus*, alongside higher levels of pro-inflammatory species.

Chronic stress – a known precipitant of anxiety – leads to increased intestinal permeability, inflammation, and dysbiosis. These changes trigger a systemic immune response that influences neuroendocrine signaling[5].

4.3 Microbial Metabolites and Neurotransmitters

Several gut microbes produce neuroactive compounds that impact mood:

- **Serotonin:** About 90% of the body's serotonin is produced in the gut. Certain bacteria (e.g., *Candida*, *Streptococcus*) can influence its synthesis[6].

- **GABA:** Produced by *Lactobacillus* and *Bifidobacterium*, GABA has calming effects and modulates stress and anxiety[7].

Mechanisms of Action

Several mechanisms have been proposed to explain how the gut microbiota influences anxiety:

- **Neurotransmitter Modulation:** Gut microbes produce and modulate key neurotransmitters involved in anxiety regulation, such as GABA, serotonin, dopamine, and norepinephrine.
- **HPA Axis Regulation:** Dysbiosis can lead to dysregulation of the HPA axis, increasing cortisol levels and stress sensitivity.
- **Inflammation:** Chronic low-grade inflammation, driven by a compromised gut barrier and microbial imbalance, is increasingly linked to anxiety and other mood disorders.
- **Vagal Signaling:** The vagus nerve is critical for conveying calming signals from the gut to the brain. Microbial changes that impair vagal tone may contribute to heightened anxiety.

SCFAs: Butyrate and propionate improve blood-brain barrier (BBB) integrity, reduce neuroinflammation, and enhance neurogenesis[8]

4.4 Inflammatory Hypothesis of Depression

A growing body of research supports the theory that chronic low-grade systemic inflammation may be a key contributor to the development and persistence of depression. This perspective shifts the focus from a purely neurochemical imbalance to a more integrated view involving the immune system and gut health. Key elements of this theory include:

- **Elevated Inflammatory Markers in Depression:** Numerous studies have shown that individuals with depression often exhibit higher levels of inflammatory markers in the blood, such as interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF- α). These markers are typically associated with immune activation and are indicative of a persistent inflammatory state, even in the absence of an infection or acute illness.
- **Gut Dysbiosis and Compromised Barrier Function:** An imbalance in the gut microbiota—referred to as dysbiosis—can weaken the intestinal barrier, often described as “leaky gut.”

This allows bacterial components like lipopolysaccharides (LPS), which are found in the outer membrane of gram-negative bacteria, to pass into the bloodstream. Once in circulation, LPS acts as a powerful trigger for the immune system, promoting widespread inflammation throughout the body.

- **Impact on Neurotransmitter Pathways:** Inflammatory cytokines can significantly disrupt brain chemistry. One of the most well-documented mechanisms involves the diversion of tryptophan, an essential amino acid and the primary precursor for serotonin. In an inflamed state, tryptophan is increasingly shunted away from serotonin production and instead metabolized through the kynurenine pathway. This not only leads to reduced serotonin availability—often associated with depressive symptoms—but also results in the production of neurotoxic metabolites like quinolinic acid (pyridine derivative), which may damage neurons and impair brain function.

4.5 Psychobiotics – A Therapeutic Frontier

“Psychobiotics” refer to probiotic strains that produce mental health benefits through the MGBA. Clinical trials have demonstrated:

- *Lactobacillus helveticus* and *Bifidobacterium longum* reduce anxiety and cortisol levels[10]
- Probiotic supplementation improved depression scores in patients with irritable bowel syndrome (IBS) and mild-to-moderate depression[11]

Additionally, dietary interventions such as high-fiber, fermented foods, and polyphenol-rich diets improve microbiota balance and reduce depression scores[12].

4.6 Limitations and Future Directions

While the gut-mood connection is biologically plausible, some challenges remain:

- Inter-individual microbiota variability makes standardization difficult
- Cause vs. correlation is hard to determine in human studies.
- Optimal strains, doses, and durations of psychobiotics remain to be defined

Future personalized microbiome-based treatments – including targeted probiotics, prebiotics, and microbiota transplants – offer promising alternatives or adjuncts to traditional psychiatric therapy.

References (Vancouver Style)

1. Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. *Trends Neurosci.* 2013;36(5):305–12.
2. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. *Brain Behav Immun.* 2015;48:186–94.
3. Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y, et al. The gut microbiome from patients with major depressive disorder modulates the depressive-like behavior in mice. *Transl Psychiatry.* 2016;6(12):e918.
4. Kim YK, Shin C. The microbiota–gut–brain axis in neuropsychiatric disorders: pathophysiological mechanisms and novel treatments. *Curr Neuropharmacol.* 2018;16(5):559–73.
5. O’Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain–gut–microbiome axis. *Behav Brain Res.* 2015;277:32–48.
6. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. *Cell.* 2015;161(2):264–76.
7. Barrett E, Ross RP, O’Toole PW, Fitzgerald GF, Stanton C. γ -Aminobutyric acid production by culturable bacteria from the human intestine. *J Appl Microbiol.* 2012;113(2):411–7.
8. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota–gut–brain communication. *Nat Rev Gastroenterol Hepatol.* 2019;16(8):461–78.
9. Maes M, Kubera M, Leunis JC. The gut–brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram-negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. *Neuro Endocrinol Lett.* 2008;29(1):117–24.
10. Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of psychotropic-like properties of a probiotic formulation (*Lactobacillus helveticus* R0052 and *Bifidobacterium*

longum R0175) in rats and human subjects. *Br J Nutr.* 2011;105(5):755–64.

11. Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, et al. Probiotic *Bifidobacterium longum* NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. *Gastroenterology.* 2017;153(2):448–59.e8.
12. Jacka FN, O’Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, et al. A randomized controlled trial of dietary improvement for adults with major depression (the SMILES trial). *BMC Med.* 2017;15(1):23.